State of Wisconsin Investment Board increased its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 33.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,274 shares of the biopharmaceutical company’s stock after acquiring an additional 2,080 shares during the period. State of Wisconsin Investment Board’s holdings in Agios Pharmaceuticals were worth $426,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Swiss National Bank grew its position in Agios Pharmaceuticals by 3.4% in the first quarter. Swiss National Bank now owns 55,360 shares of the biopharmaceutical company’s stock worth $3,233,000 after acquiring an additional 1,800 shares in the last quarter. Spark Investment Management LLC grew its position in Agios Pharmaceuticals by 139.9% in the second quarter. Spark Investment Management LLC now owns 84,700 shares of the biopharmaceutical company’s stock worth $4,357,000 after acquiring an additional 49,400 shares in the last quarter. Geode Capital Management LLC grew its position in Agios Pharmaceuticals by 8.3% in the first quarter. Geode Capital Management LLC now owns 263,899 shares of the biopharmaceutical company’s stock worth $15,410,000 after acquiring an additional 20,336 shares in the last quarter. TD Asset Management Inc. grew its position in Agios Pharmaceuticals by 4.9% in the second quarter. TD Asset Management Inc. now owns 30,000 shares of the biopharmaceutical company’s stock worth $1,544,000 after acquiring an additional 1,400 shares in the last quarter. Finally, Hamilton Lane Advisors LLC purchased a new position in Agios Pharmaceuticals in the second quarter worth about $2,890,000. Institutional investors own 94.30% of the company’s stock.

Agios Pharmaceuticals, Inc. (AGIO) opened at 65.82 on Thursday. Agios Pharmaceuticals, Inc. has a 12 month low of $39.24 and a 12 month high of $67.74. The stock’s market cap is $3.19 billion. The firm’s 50 day moving average price is $59.52 and its 200 day moving average price is $54.17.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.21). The business had revenue of $11.30 million during the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The firm’s revenue was up 62.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.47) EPS. On average, equities research analysts predict that Agios Pharmaceuticals, Inc. will post ($7.07) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/14/state-of-wisconsin-investment-board-buys-2080-shares-of-agios-pharmaceuticals-inc-agio.html.

In other news, CEO David P. Schenkein sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $51.18, for a total transaction of $153,540.00. Following the completion of the sale, the chief executive officer now owns 3,000 shares in the company, valued at approximately $153,540. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Scott Biller sold 2,146 shares of the firm’s stock in a transaction that occurred on Friday, July 7th. The stock was sold at an average price of $55.00, for a total transaction of $118,030.00. Following the sale, the insider now owns 8,410 shares of the company’s stock, valued at approximately $462,550. The disclosure for this sale can be found here. Insiders have sold a total of 99,230 shares of company stock valued at $5,918,142 in the last 90 days. Insiders own 10.55% of the company’s stock.

Several research analysts recently commented on the company. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $83.00 price target (up previously from $75.00) on shares of Agios Pharmaceuticals in a research report on Thursday, August 10th. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $80.00 price target (up previously from $68.00) on shares of Agios Pharmaceuticals in a research report on Tuesday, August 8th. Leerink Swann upgraded Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $50.00 to $80.00 in a research report on Wednesday, August 2nd. Cann reiterated a “buy” rating and issued a $75.00 price target on shares of Agios Pharmaceuticals in a research report on Sunday, June 11th. Finally, Janney Montgomery Scott reiterated a “hold” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, August 1st. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $74.75.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.